Analyzing oral tumors using differential mobility spectrometry
Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
This study is testing a new way to analyze tissue during surgery for oral cancer to see if it can help doctors tell the difference between tumor cells and healthy tissue.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 40 Years to 90 Years |
| Sex | All |
| Sponsor | Tampere University Hospital Academic / other |
| Locations | 1 site (Tampere, Pirkanmaa) |
| Trial ID | NCT05902455 on ClinicalTrials.gov |
What this trial studies
This observational trial evaluates the feasibility of using differential mobility spectrometry (DMS) to analyze tissue smoke generated during the surgical excision of oral squamous cell carcinoma. Patients undergoing standard-of-care tumor removal surgery will have their tissue analyzed to identify tumor cells versus healthy tissue. The study aims to improve the understanding of healthy tissue margins, which are crucial for successful surgical outcomes. By utilizing automatic tissue analysis (ATAS), the research seeks to enhance diagnostic accuracy in real-time during surgery.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with operable oral squamous cell carcinoma with tumors measuring 2 cm or larger.
Not a fit: Patients with tumors smaller than 2 cm or those unwilling to participate in the trial may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more precise surgical removal of tumors, improving patient outcomes and survival rates.
How similar studies have performed: While the use of DMS in this context is relatively novel, similar approaches in tissue analysis have shown promise in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Biopsy diagnosed oral squamous cell carcinoma. * Tumor diameter of 2 cm or larger. * Operable patient that is willing to participate in the trial. Exclusion Criteria: * Tumor diameter less than 2 cm. * Patient that is unwilling to take part in the trial. * Patient that is not able to understand given information concerning the trial or to give concent to take part in the trial.
Where this trial is running
Tampere, Pirkanmaa
- Tampere University Hospital — Tampere, Pirkanmaa, Finland (Recruiting)
Study contacts
- Study coordinator: Anni Salminen, M.D.
- Email: anni.h.salminen@tuni.fi
- Phone: +358503467184
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.